FDA Approves Sugammadex for Reversing Neuromuscular Blockade

Published on: December 18th, 2015

The FDA has approved sugammadex (Bridion; Merck Sharp and Dohme Corp.) to reverse the effects of the neuromuscular blocking drugs rocuronium bromide and vecuronium bromide.  The drugs are used to temporarily paralyze the vocal cords of adult patients who require tracheal intubation, and can also be used to prevent movement during surgery for patients receiving general anesthesia.

See more here.

Topics: None